Jiangxi Fushine Pharmaceutical Co Ltd (300497) — Working Capital to Net Assets Ratio
Jiangxi Fushine Pharmaceutical Co Ltd (300497) has a Working Capital to Net Assets ratio of 12.3% as of March 2026. Working capital of CN¥279.40 Million (current assets of CN¥1.55 Billion minus current liabilities of CN¥1.27 Billion) is measured against net assets of CN¥2.27 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300497 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jiangxi Fushine Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 12.3%, reflecting working capital of CN¥279.40 Million against net assets of CN¥2.27 Billion CNY. For the complete balance sheet picture, see 300497 total assets.
Annual Working Capital to Net Assets for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 300497 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 8.7% | CN¥192.09 Million | CN¥2.20 Billion | CN¥1.46 Billion | CN¥1.27 Billion | ▲ +2.4 pp |
| 2024 | 6.3% | CN¥137.20 Million | CN¥2.18 Billion | CN¥1.68 Billion | CN¥1.54 Billion | ▼ -17.7 pp |
| 2023 | 24.0% | CN¥591.84 Million | CN¥2.47 Billion | CN¥1.88 Billion | CN¥1.29 Billion | ▼ -12.1 pp |
| 2022 | 36.1% | CN¥970.42 Million | CN¥2.69 Billion | CN¥2.23 Billion | CN¥1.26 Billion | ▲ +3.4 pp |
| 2021 | 32.7% | CN¥951.59 Million | CN¥2.91 Billion | CN¥2.31 Billion | CN¥1.36 Billion | ▼ -15.9 pp |
| 2020 | 48.6% | CN¥1.48 Billion | CN¥3.05 Billion | CN¥2.37 Billion | CN¥884.90 Million | ▲ +5.1 pp |
| 2019 | 43.5% | CN¥664.77 Million | CN¥1.53 Billion | CN¥1.39 Billion | CN¥725.28 Million | ▲ +18.5 pp |
| 2018 | 25.1% | CN¥287.25 Million | CN¥1.15 Billion | CN¥1.25 Billion | CN¥962.02 Million | ▼ -9.1 pp |
| 2017 | 34.1% | CN¥329.93 Million | CN¥966.71 Million | CN¥1.01 Billion | CN¥675.98 Million | ▼ -11.1 pp |
| 2016 | 45.2% | CN¥354.68 Million | CN¥784.17 Million | CN¥860.58 Million | CN¥505.90 Million | ▼ -9.4 pp |
| 2015 | 54.6% | CN¥325.74 Million | CN¥596.21 Million | CN¥627.53 Million | CN¥301.79 Million | ▲ +45.2 pp |
| 2014 | 9.5% | CN¥26.79 Million | CN¥283.26 Million | CN¥303.20 Million | CN¥276.41 Million | ▼ -1.6 pp |
| 2013 | 11.0% | CN¥25.38 Million | CN¥229.76 Million | CN¥244.99 Million | CN¥219.61 Million | ▲ +18.3 pp |
| 2012 | -7.2% | CN¥-13.36 Million | CN¥184.60 Million | CN¥231.80 Million | CN¥245.16 Million | ▼ -6.6 pp |
| 2011 | -0.6% | CN¥-778.93K | CN¥120.52 Million | CN¥183.94 Million | CN¥184.72 Million | — |